IDXX
NASDAQIDEXX Laboratories Inc.
Price$519.45-0.93 (-0.18%)
01:30 PM07:15 PM
News · 26 weeks42-33%
2026-03-292026-09-20
Mix1290d
- Other4(33%)
- Insider3(25%)
- Earnings2(17%)
- SEC Filings2(17%)
- M&A1(8%)
Latest news
25 items- PRIDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm DetectionExpanded testing menu now detects more intestinal parasites during routine visits IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than faecal flotation alone,1 Faecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917879004/en/IDEXX Faecal Dx™ ant
- PRIDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow IntelligenceAcquisition strengthens IDEXX’s connected diagnostic and software ecosystem with AI-native workflow capabilities that enhance efficiency, clinical decision-making, and diagnostic utilization IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. Serving both multipractice corporate groups and independent veterinary practices worldwide, CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment plan
- INSIDERDirector Kingsley Lawrence D exercised 2,203 shares at a strike of $114.17 and sold $1,172,178 worth of shares (2,203 units at $532.08) (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- PRIDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare ConferenceIDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET). A live audio webcast of the fireside chat will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the fireside chat will be available via the same link. About IDEXX Laboratories, Inc. IDEXX is a global leader in pet healthcare innovation. Our diagnos
- INSIDEREVP, CFO and Treasurer Emerson Andrew exercised 265 shares at a strike of $178.26 and covered exercise/tax liability with 86 shares, increasing direct ownership by 4% to 4,421 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- PRIDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP TestNew test brings quantitative cardiac assessment for cats and dogs into everyday workflows IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst™ proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a well-established biomarker used to evaluate heart disease in companion animals, a condition that affects approximately 1 in 6 cats1 and 1 in 10 dogs2, yet remains underassessed in general practice. Available on the Catalyst platform with a global installed base of nearly 80,000
- SECSEC Form 10-Q filed by IDEXX Laboratories Inc.10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- SECIDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- PRIDEXX Laboratories Announces Second Quarter ResultsAchieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics utilization. IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter. Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as reported and 110 basis points on a comparable basis. Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5 million at midp
- INSIDERDirector Hooley Joseph L was granted 49 shares, increasing direct ownership by 18% to 325 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- PRIDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its GoalsIDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today released its 2025 Corporate Responsibility Report, highlighting progress against the company’s goals and commitments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728755319/en/2025 IDEXX Corporate Responsibility Report "At IDEXX, corporate responsibility is central to how we create long-term value," said Mike Erickson, IDEXX President and Chief Executive Officer. "The progress reflected in this report is the result of sustained investments in innovation, our people, and capabilities that support our customers every day. These priorit
- PRIDEXX Laboratories to Release 2026 Second Quarter Financial ResultsIDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2026 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen
- INSIDERExecutive Vice President Fennell George converted options into 639 shares and covered exercise/tax liability with 284 shares, increasing direct ownership by 4% to 10,433 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- SECSEC Form SD filed by IDEXX Laboratories Inc.SD - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- PRIDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm DetectionThird menu expansion in four years broadens intestinal parasite detection in routine care IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Fecal Dx™ antigen testing platform with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than fecal flotation alone,1 Fecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526203257/en/IDEXX Fecal Dx™ antigen testing platf
- PRIDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry ProfilesBuilt-in SDMA delivers earlier insights with seamless workflow IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that SDMA, a renal biomarker, will be built into Catalyst™ CLIPs, making complete kidney function evaluation part of the most common point-of-care chemistry profiles. Available beginning in June to customers in the United States and Canada, the integration expands access to advanced kidney assessment at scale, enabling veterinarians to identify kidney function loss earlier and act sooner, without disrupting familiar workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/new
- PRThe Biology Came First.Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's work today. MindWalk Holdings Corp. (NASDAQ:HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, the clinical asset is
- SECIDEXX Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- INSIDERSEC Form 4 filed by Director Samad Sam4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERSEC Form 4 filed by Director Vandebroek Sophie V.4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERSEC Form 4 filed by Director Peacock Karen4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERSEC Form 4 filed by Director Junius Daniel M4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERSEC Form 4 filed by Director Kingsley Lawrence D4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERSEC Form 4 filed by Director Hooley Joseph L4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERSEC Form 4 filed by Director Claflin Bruce L.4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
IDXX FAQ
7 questionsWhat does IDEXX Laboratories Inc. do?
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health...Where does IDXX stock trade?
IDEXX Laboratories Inc. (IDXX) is listed on NASDAQ.What sector and industry is IDXX in?
IDEXX Laboratories Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did IDEXX Laboratories Inc. go public?
IDEXX Laboratories Inc. (IDXX) completed its IPO in 1991.What are analysts saying about IDXX?
IDEXX Laboratories Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral on 2026-04-15.What companies are similar to IDXX?
Notable peers in the same industry include LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), NEOG (Neogen Corporation), CLDX (Celldex Therapeutics Inc.). Compare IDXX side-by-side with any of them on Quantisnow.How can I track IDXX on Quantisnow?
Quantisnow aggregates IDEXX Laboratories Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IDXX to receive live email and push alerts on every new disclosure.